Ironwood Paying $1bn For VectivBio To Extend Its GI Franchise Beyond Linzess

Phase III Data For Apraglutide Due In Late 2023

 
• By Mandy Jackson
  
White jigsaw puzzle pieces connecting together on a light blue background
Ironwood sees VectivBio's apraglutide as a good fit in its gastrointestinal portfolio • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business